symporter

(redirected from Co-transporters)
Also found in: Medical.

symporter

[sim′pȯrd·ər]
(cell and molecular biology)
A channel protein that simultaneously transports two different types of substrates (for example, sodium ion plus glucose) across a cell membrane, both in the same direction.
References in periodicals archive ?
XRpro has the unique ability to perform functional assays in 100% serum and for complicated non-electrogenic co-transporters which we deem to be critical needs of the industry.
Quantification of mRNA levels of the Na-Pi co-transporters showed a significant increase of NaPi-IIb mRNA levels in the ileum of chickens fed the 0.
SGLT2 is a subtype of the sodium-glucose co-transporters and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys.
It appears that a major function of circulating FGF23 is the control of the expression of the renal tubular sodium dependent phosphate co-transporters (NaPi 2a and 2c) and thus renal tubular phosphate reabsorption.
1) Reduction of Energy Uptake from the GI and Genitourinary Tract 1a) Inhibitors of Panreatic Lipase 1b) Inhibitors of Intestinal Microsomal Trigliceride Transfer Protein (MTP) 1c) Inhibitors of Acyl-CoA:diacyl-glycerol acyltransfe-rase 1 (DGAT1) 1d) Inhibitors of Low-Affinity Sodium-Dependent Glucose Co-transporters (SGLT2) 1e) Others
The SGLT disease education campaign provides resources for healthcare professionals about the role of sodium glucose co-transporters in maintaining blood sugar balance
Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin [D.
LX4211, an investigational, oral, dual inhibitor of sodium glucose co-transporters 1 and 2 (SGLT1 and SGLT2), reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney.
Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).